35,000 asthma patients under the microscope: Real-World dupilumab use revealed

NCT ID NCT07637292

Ongoing Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how dupilumab, a drug for severe asthma, is actually used by patients in France. Researchers will analyze health records of about 35,000 people to describe their characteristics, healthcare costs, and steroid use before and after starting the drug. The goal is to understand real-world effectiveness and patterns, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab
What this could lead to: If successful, this study could provide insights into how dupilumab is used in everyday practice for severe asthma, potentially guiding better treatment decisions.
What could go wrong: This is an observational study analyzing existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute asthma chronic asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA ACUTE

Contacts and locations

Locations

Hospices Civils de Lyon

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.